Rachna Shroff
Coverage of Rachna Shroff in the Nexus archive.
- Promising pancreatic cancer treatment doubles survival rates
An experimental drug for pancreatic cancer, taken once daily, has shown promising results in slowing cancer progression and extending patient survival. Dr. Rachna Shroff from the University of Arizona Comprehensive Cancer Center discusses the treatment's potential.
- Experimental pill promises new hope for deadly pancreatic cancer
A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a clinical trial. The drug targets a mutated protein present in over 90% of pancreatic cancer cases and showed fewer severe side effects, with patients reporting better quality of life.
- STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
A clinical trial of daraxonrasib, a pancreatic cancer drug developed by Revolution Medicines, showed patients lived nearly twice as long as those receiving standard chemotherapy. Results were presented at the American Society of Clinical Oncology meeting and published in the New England Journal of Medicine.